EP
RLMD icon

Eversept Partners’s Relmada Therapeutics RLMD Stock Holding History

Eversept Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645K Sell
93,192
-184,707
-66% -$1.29M 0.03% 111
2026
Q1 		$1.93M Buy
+277,899
New +$1.31M 0.1% 89

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners's RLMD Position: Q2 2026 in Review

Eversept Partners reduced its Relmada Therapeutics (RLMD) stake by 66% in Q2 2026, selling an estimated $1.29M and leaving 93,192 shares worth $645K. The position accounts for 0.03% of the portfolio, ranked #111.

Eversept Partners first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.93M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Eversept Partners held 93,192 shares of Relmada Therapeutics worth $645K as of Q2 2026.
  • Eversept Partners sold 184,707 Relmada Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Relmada Therapeutics made up 0.03% of Eversept Partners's portfolio in Q2 2026, its #111 holding.
  • Eversept Partners first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Eversept Partners's Relmada Therapeutics position peaked at $1.93M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.